Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Atugen and Byk Gulden Study T Cells With Antisense

NEW YORK, May 14-The German firm Atugen will collaborate on a three year functional genomics research project with Byk Gulden, the pharmaceutical group of Altana AG.

 

Atugen will validate genetic targets associated with cancer and immunological disease, and develop "GeneBloc" antisense oligonucleotides against these targets. The two companies will use these probes to jointly conduct functional genomics studies in assays and animal models.

 

The partnership will especially focus on genetic targets in T cells for treatment of inflammatory disease.

 

Atugen will get an upfront payment, annual licensing fees, research funding and milestone payments, as well as royalties on any probes developed as therapeutics. The company retains rights to all GeneBloc oligonucleotides, and may further develop any targets not pursued by Byk Gulden.

 

This collaboration builds upon another established last fall, when the two companies agreed to jointly develop cancer-related gene targets.

 

Atugen is headquartered in Berlin, with a subsidiary in Boulder, Colo.

 

Byk Gulden, based in Constance, Germany, specializes in therapeutics for gastrointestinal, respiratory tract, and cardiovascular conditions.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.